Correction of Underquantification of Human Immunodeficiency Virus Type 1 Load with the Second Version of the Roche Cobas AmpliPrep/Cobas TaqMan Assay

Bel, Annelies De; Marissens, D.; Debaisieux, Laurent; Liesnard, Corinne; Wijngaert, S. Van den; Lauwers, S.; Piérard, Denis

doi:10.1128/jcm.01226-09

Cited by 22 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be due, at least in part, to genetic differences between integrase and gag/LTR regions. The poor recognition by CAP/ CTM v1.0 of non-B subtypes was previously described by others (8,10), and De Bel et al recently also reported an underquantification with some B subtype strains (3). Indeed, the ability of the CAP/CTM assay to recognize non-B subtypes was dramatically improved between v1.0 and v2.0 (17; this study).…”

Section: Discussionsupporting

confidence: 50%

“…The CAP/CTM v1.0 consists of an automated RNA extraction (input volume of 1.0 ml, AmpliPrep instrument) followed by a gag fragment amplification by real-time PCR using a fluorescent TaqMan probe (Cobas TaqMan apparatus) (16). Compared to the previous version 1.0, the CAP/CTM v2.0 targets both gag and LTR regions and exhibits a dynamic range of 20 to 10 7 HIV RNA copies/ml (versus 40 to 10 7 for version 1.0) (3,17). HIV-1 subtype.…”

Section: Methodsmentioning

confidence: 99%

“…This point is a major criterion to be considered for the development of assays able to amplify the different HIV-1 subtypes. Indeed, recent data have suggested viral load discrepancies between commercial quantitative assays, especially for the quantification of non-B subtype strains (2,3,8,20). To achieve a high sensitivity threshold, a judicious choice of HIV-1 gene targets, primers, and probes is critical.…”

mentioning

confidence: 99%

See 2 more Smart Citations

HIV-1 Load Comparison Using Four Commercial Real-Time Assays

Bourlet¹,

Signori-Schmück

Roche

et al. 2011

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

HIV-1 Load Comparison Using Four Commercial Real-Time Assays

Bourlet¹,

Signori-Schmück

Roche

et al. 2011

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…A summary of the current EQAPOL panel is provided in Table 2. Viral load was quantified using the Roche COBAS Taqman Version 2.0 assay, which can quantify a broad range of subtypes, including Group O (De Bel et al, 2010). The average culture supernatant final product concentration was 4.20 × 10 9 cp/mL, and the average p24 was 206.59 ng/mL (Table 3).…”

Section: Resultsmentioning

confidence: 99%

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program

Sánchez

DeMarco

Hora

et al. 2014

Journal of Immunological Methods

View full text Add to dashboard Cite

The significant diversity among HIV-1 variants poses serious challenges for vaccine development and for developing sensitive assays for screening, surveillance, diagnosis and clinical management. Recognizing a need to develop a panel of HIV representing the current genetic and geographic diversity NIH/NIAID contracted the External Quality Assurance Program Oversight Laboratory (EQAPOL) to isolate, characterize and establish panels of HIV-1 strains representing global diverse subtypes and circulating recombinant forms (CRFs), and to make them available to the research community. HIV-positive plasma specimens and previously established isolates were collected through a variety of collaborations with a preference for samples from acutely/recently infected persons diagnosed since 2009. Source specimens were cultured to high-titer/high-volume using well-characterized cryopreserved PBMCs from healthy donors. Panel samples were stored as neat culture supernatant or diluted into defibrinated plasma. Characterization for the final expanded virus stocks included viral load, p24 antigen, infectivity (TCID), sterility, coreceptor usage, and near full-length genome sequencing. Viruses are made available to approved, interested laboratories using an online ordering application. The current EQAPOL Viral Diversity panel includes over 101 viral specimens representing 6 subtypes (A, B, C, D, F, and G), 2 sub-subtypes (F1 and F2), 7 CRFs (01, 02, 04, 14, 22, 24, and 47), 19 URFs and 3 group O viruses from 22 countries. The EQAPOL Viral Diversity panel is an invaluable collection of well-characterized reagents that are available to the scientific community, including researchers, epidemiologists, and commercial manufacturers of diagnostics and pharmaceuticals to support HIV research and diagnostic and vaccine development.

show abstract

“…All viral load tests in British Columbia are performed at the virology laboratory at St Paul's hospital and are uploaded automatically in the DTP database. As the quantification range of viral load assays has evolved over time, for analytical purposes, we truncated our measurements to range from less than 50 (coded as 49) to more than 100000 (coded as 100010) copies/ml [38–41]. HIV drug resistance genotyping is routinely performed at the BC-CfE virology laboratory on samples with viral loads of at least 250 copies/ml upon physician request.…”

Section: Methodsmentioning

confidence: 99%

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes

Lima

Reuter

Harrigan

et al. 2015

Aids

View full text Add to dashboard Cite

Objective There is limited research investigating the possible mechanisms of how starting combination antiretroviral therapy (cART) at a higher CD4+ cell count decreases mortality. This study investigated the association between initiating cART with short-term and long-term achievement of viral suppression; emergence of any drug resistance and of an AIDS-defining illness (ADI); long-term treatment adherence; and all-cause mortality. Methods This retrospective cohort study included 4120 naive patients who initiated cART between 2000 and 2012. Patients were followed until 2013, death or until the last contact date (varied by outcome). The main exposure was the interaction between period of cART initiation (2000–2006 and 2007–2012) and CD4+ cell count at cART initiation (<500 versus ≥500 cells/μl). We considered both baseline and longitudinal covariates. We fitted different multivariable models using cross-sectional and longitudinal statistical methods, depending on the outcome. Results Patients who initiated cART with a CD4+ cell count at least 500cells/μl in 2007–2012 had an increased likelihood of achieving viral suppression at 9 months and of maintaining an adherence level of at least 95% overtime, and the lowest probability of developing any resistance and an ADI during follow-up. These patients were not the ones with the highest likelihood of maintaining viral suppression over time, most likely due to viral load blips experienced during the follow-up. Conclusion The outcomes in this study likely play an important role in explaining the positive impact of early cART initiation on mortality. These results should alleviate some of the concerns clinicians may have when initiating cART in patients with high CD4+s as recommended by current treatment guidelines.

show abstract

Correction of Underquantification of Human Immunodeficiency Virus Type 1 Load with the Second Version of the Roche Cobas AmpliPrep/Cobas TaqMan Assay

Cited by 22 publications

References 16 publications

HIV-1 Load Comparison Using Four Commercial Real-Time Assays

HIV-1 Load Comparison Using Four Commercial Real-Time Assays

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes

Contact Info

Product

Resources

About